Nalaganje...
Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
PURPOSE: Long-term persistence with pharmacotherapy for overactive bladder (OAB) requires a drug with an early onset of action and good efficacy and tolerability profile. Although antimuscarinics improve OAB symptoms within 1–2 weeks of initiating treatment, adherence after 3 months is relatively po...
Shranjeno v:
| izdano v: | World J Urol |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Berlin Heidelberg
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4236626/ https://ncbi.nlm.nih.gov/pubmed/24458878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00345-014-1244-2 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|